TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.
TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.
This report „TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals“ published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.
Download Sample Pages: TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).
Key questions answered:
- Which targets are chosen for developmen of TCR-Ts?
- How close are neoantigen-specific TCR-Ts to the clinic?
- Which technologies are used for generation of T-Cell Receptors?
- Has clinical proof-of-concept been shown for any TCR-T?
- How does the TCR-T pipeline look like?
- What manufacturing strategies and solutions have companies chosen?
- Are next generation TCR-Ts already in development?
- What are the key technologies for a successful TCR-T?
- Who are the key players in the TCR-T field?
- How tough is competition among TCR-T developers?
- Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
- Which technologies and assets attract licensees?
- How is the financing situation for TCR-T?
- What are the key success factors for TCR-Ts?
Target audience:
- Leading Pharmaceutical companies
- Suppliers
- Contractors
- Technologists
- R&D staff
- Consultants
- Analyst
- CSO’s
- CEO’s
- CIO’s
- COO’s
- Business development managers
- Investors
- Governments
- Agencies
- Industry organisations
- Banks
Table of Contents
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Table of Contents
1Â Â Â Â Â Â Â Â Â Executive Summary
2Â Â Â Â Â Â Â Â Â Introduction, Overview & Background
3Â Â Â Â Â Â Â Â Â Technologies
3.1Â Â Â Â Â Â Overview & Discussion
3.1.1Â Â Â Technologies for Discovery of Antigens for TCRs
3.1.2Â Â Â Technologies for Discovery of TCRs
3.1.3Â Â Â Allogeneic T-Cell Technologies
3.1.4Â Â Â Technologies for Next Generation TCR T-Cells
3.2Â Â Â Â Â Â Technologies for Discovery of Targets for TCRs
3.2.1Â Â Â XPRESIDENT
3.2.2Â Â Â Target Selection for SPEAR T-Cells
3.2.3Â Â Â Phosphopeptide Library
3.2.4Â Â Â HTS Platform for Neoantigen Identification
3.2.5Â Â Â pMHC Target Discovery
3.2.6Â Â Â EpiTarget Platform
3.2.7Â Â Â Neoantigen Prediction
3.3Â Â Â Â Â Â Technologies for TCR Discovery
3.3.1Â Â Â SPEAR T-Cell Technology
3.3.2Â Â Â High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
3.3.3Â Â Â Single Cell Sequencing Platform
3.3.4Â Â Â TCR-GENErator
3.3.5Â Â Â HTS TCR Discovery and Sleeping-Beauty Expression System
3.3.6Â Â Â Natural, High Affinity TCRs (Bellicum)
3.3.7Â Â Â High-throughput cloning and characterisation of naturally selected TCRs
3.3.8Â Â Â Natural TCR Library
3.3.9Â Â Â Natural TCRs from Vaccinated Patients
3.3.10Â T-Rx Mammalian TCR Display
3.3.11Â VelociT for T-Cell Receptor Discovery
3.3.12Â Combinatorial TCR Exchange (CTE)
3.3.13Â Immune Repertoire Capture
3.3.14Â E-ALPHA Phage Display
3.3.15Â TCRL Antibodies
3.3.16Â ACTolog
3.3.17Â NEO-STIM
3.4Â Â Â Â Â Â TCR Engineered Allogeneic T-Cells
3.4.1Â Â Â ACTallo
3.4.2Â Â Â universal Immune Cell Therapies (uICT)
3.4.3Â Â Â GammaDelta T-Cells
3.4.4Â Â Â Universal Donor Stem Cells
3.4.5Â Â Â ATO Allogeneic T-Cells
3.5Â Â Â Â Â Â Next Generation Technologies to Improve Safety & Efficacy
3.5.1Â Â Â ARTEMIS Technology
3.5.2Â Â Â CID Technology Platform
3.5.3Â Â Â Custom Cell Engineering Technologies synNotch and Throttle
3.5.4Â Â Â DEACT Technology
3.5.5Â Â Â Dominant TCR Technology
3.5.6Â Â Â RetroNectin and siTCR Vector Technologies
3.5.7Â Â Â Stem-to-T-Cell Technology
3.5.8Â Â Â Transmembrane Immunomodulatory Protein (TIP) Technology
4Â Â Â Â Â Â Â Â Â Pipeline
4.1Â Â Â Â Â Â Overview & Discussion
4.1.1Â Â Â Proof-of-concept
4.1.2Â Â Â Target Selection
4.1.3Â Â Â T-Cell Sources & Subtypes
4.1.4Â Â Â Use of Switches & Next Generation Constructs
4.2Â Â Â Â Â Â Profiles of MAGE-A Specific TCR T-Cells
4.2.1Â Â Â KITE-718
4.2.2Â Â Â MAGE-A4c1032 T
4.2.3Â Â Â MAGE-A10c796 T
4.2.4Â Â Â TBI-1201
4.3Â Â Â Â Â Â Profiles of NY-ESO-1 Specific TCR T-Cells
4.3.1Â Â Â GSK3377794
4.3.2Â Â Â NYCE T Cells
4.3.3Â Â Â TBI-1301
4.4Â Â Â Â Â Â Profiles of AFP Specific TCR T-Cells
4.4.1Â Â Â AFPc332 T
4.4.2Â Â Â ET1402L1 CAR T-Cells
4.5Â Â Â Â Â Â Profiles of PRAME Specific TCR T-Cells
4.5.1Â Â Â BPX-701
4.5.2Â Â Â MDG1011
4.5.3Â Â Â Dual Switch PRAME TCR T-Cells
4.6Â Â Â Â Â Â Profiles of WT1 Specitic TCR T-Cells
4.6.1Â Â Â CMD-602
4.6.2Â Â Â JTCR016
4.6.3Â Â Â WT1-Specific Transgenic T-Cells
4.7Â Â Â Â Â Â Profiles of Other Target Specific TCR T-Cells
4.7.1Â Â Â IMA201
4.7.2Â Â Â KITE-439
4.7.3Â Â Â LTC-H1
4.7.4Â Â Â TC-210
4.7.5Â Â Â ZI-H04
4.7.6Â Â Â ZI-T01
4.8Â Â Â Â Â Â Profiles of Neoantigen Specific TCR T-Cells
4.8.1Â Â Â IMA101
4.8.2Â Â Â NEO-PTC-01
5Â Â Â Â Â Â Â Â Â Manufacturing
6Â Â Â Â Â Â Â Â Â Companies
6.1Â Â Â Â Â Â Company Overview & Discussion
6.1.1Â Â Â Pure Play TCR T-Cell Companies
6.1.2Â Â Â Diversified Companies with TCR-T Activities
6.2 Â Â Â Â Â Pure Play TCR T-Cell Companies
6.2.1Â Â Â Adaptimmune Therapeutics
6.2.2Â Â Â Gadeta
6.2.3Â Â Â Immatics US
6.2.4Â Â Â Lion TCR
6.2.5Â Â Â Tactiva Therapeutics
6.2.6Â Â Â Zelluna Immunotherapies
6.2.7Â Â Â TCR2 Therapeutics
6.3Â Â Â Â Â Â Profiles of Diversified Companies with TCR-T Activities
6.3.1Â Â Â Adicet Bio
6.3.2Â Â Â AgenTus Therapeutics
6.3.3Â Â Â Bellicum Pharmaceuticals
6.3.4Â Â Â BioNTech
6.3.5Â Â Â Bluebird bio
6.3.6Â Â Â Cell Medica
6.3.7Â Â Â Eureka Therapeutics
6.3.8Â Â Â GlaxoSmithKline
6.3.9Â Â Â Intellia Therapeutics
6.3.10Â Juno, a Celgene Company
6.3.11Â Kite, a Gilead Company
6.3.12Â Medigene
6.3.13Â Neon Therapeutics
6.3.14Â Regeneron Pharmaceuticals
6.3.15Â Takara Bio
6.3.16Â TC BioPharm
6.3.17Â Tmunity Therapeutics
6.3.18Â ZIOPHARM Oncology
6.4Â Â Â Â Â Â Other Companies with TCR-T Activities
6.4.1Â Â Â Alpine Immune Sciences
6.4.2Â Â Â Atreca
6.4.3Â Â Â ImmunoCellular Therapeutics
7Â Â Â Â Â Â Â Â Â Business Development & Financing
7.1Â Â Â Â Â Â Role of academia for the TCR-T industry
7.2Â Â Â Â Â Â Role of Big Pharma & Biotech for TCR-T
7.3Â Â Â Â Â Â Technology In-Licensing Deals
7.4Â Â Â Â Â Â Collaborative Arrangements
7.5Â Â Â Â Â Â Acquisitions of Companies and Assets
7.6Â Â Â Â Â Â Financing of TCR-T Companies
8Â Â Â Â Â Â Â Â Â Outlook & Perspectives
9Â Â Â Â Â Â Â Â Â References
Tables
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Tables in the Text
Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
Table 5: Overview of TCR T-Cell Constructs in Development
Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
Table 7: Overview of in-house Company Manufacturing Solutions
Table 8: Overview of Company Choices of CMO
Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
Table 10: Overview of TCR T-Cell Company Profiles
Table 11: Overview of Profiles of Pure Play TCR-T Companies
Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
Table 13: Adaptimmune’s Pipeline of SPEAR T-Cells
Table 14: TCR T-cell Pipeline of Lion TCR
Table 15: TCR2 Therapeutics’ TRuC-T Cell Pipeline
Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
Table 17: Bellicum Pharmaceuticals’ Pipeline
Table 18: Cell Medica’s Pipeline
Table 19: Overview of Kite Pharma’s Access to Technologies with Focus on TCR
Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
Table 21: TC BioPharm’s Pipeline of γδ T-cell programs
Table 22: Clinical Pipeline of Tmunity Therapeutics
Table 23: Technology Spin-Out from Academia
Table 24: Deals with Major Pharma & Biotech
Table 25: Technology In-Licensing from Pharma & Biotech
Table 26: Collaborations & Joint Ventures
Table 27: Acquisitions
Table 28: Financing Sources of Pure Play TCR-T Companies
Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities